American College of Cardiology
Mixed results for AstraZeneca in high-profile Brilinta study
March 17, 2015Sales and Marketing American College of Cardiology, AstraZeneca, Brilinta, EMA, FDA, ticagrelor
Experts say AstraZeneca is at risk of ‘diminishing returns’ in the clinical advantages of its blood-thinning drug Brilinta, after it …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
